Systemic Treatment of Patients With Metastatic Breast Cancer
Key Points
Key Points
- Palliative care needs should be addressed for all patients at presentation of metastatic breast cancer (MBC), including situations in which no antineoplastic interventions are accessible.
- Patients who are premenopausal can receive aromatase inhibitors only if accompanied by ovarian ablation or ovarian suppression.
- Clinicians should recommend treatment according to pathological and biomarker features when quality (following established guidelines) testing results are available.
- Cases should be discussed using a multidisciplinary approach with the core team including the surgeon, pathologist, oncologist, and radiation oncologist.
Table 1. Framework of Resource Stratification
| Setting | |
|---|---|
| Basic | Core resources or fundamental services that are absolutely necessary for any public health/primary health care system to function; basic-level services typically are applied in a single clinical interaction. Vaccination is feasible for highest need populations. |
| Limited | Second-tier resources or services that are intended to produce major improvements in outcome such as incidence and cost-effectiveness and are attainable with limited financial means and modest infrastructure; limited-level services may involve single or multiple interactions. Universal public health interventions feasible for greater percentage of population than primary target group. |
| Enhanced | Third-tier resources or services that are optional but important; enhanced-level resources should produce further improvements in outcome and increase the number and quality of options and individual choice. (Perhaps ability to track patients and links to registries). |
| Maximal | May use high-resource settings’ guidelines. High-level/state-of-the-art resources or services that may be used/available in some high-resource countries and/or may be recommended by high-resource setting guidelines that do not adapt to resource constraints but that nonetheless should be considered a lower priority than those resources or services listed in the other categories on the basis of extreme cost and/or impracticality for broad use in a resource-limited environment. |
Treatment
...eatment...
...osis, Staging, and Treatment Capacitie...
...rst-line...
...eceptor-positive (HR-positive)...
...tive...
Triple-negative...
Second-line
...In Enha...
...ve...
...tive, BRCA1/2 mutations...
...In sec...
...ird-line...
...e-negative...
...le 3. First-Line Systemic Metastatic...
...sic settings, the recommendations presume that n...
...Positive, HER2-Nega...
1.1.1
...Tamoxifen, palliative,* and best supportive...
...ted Sequential hormone therapy**...
...quential hormone therapy** (, , , )1048203...
1.1....
...fen Palliative* and best supportive care (, ,...
Limited Single-agent chemotherapy Combination...
...Single-agent chemotherapy Combination re...
....1.3...
...ic Tamoxifen Palliative* and be...
...ngle-agent chemotherapy Combination re...
...Single-agent chemotherapy Combination r...
1.1....
...amoxifen (, , , )10482...
Limited Tamoxifen (Nonsteroidal AI if a...
...hanced A nonsteroidal AI** and a CDK4/6...
....1.5
...asic Tamoxifen Bilateral oophore...
...mited Tamoxifen or alternate hormon...
Enhanced Ovarian suppression or ablation...
1.1....
...Tamoxifen (, , , )1048203
...fen or AI** Nonsteroidal if available fo...
...d Nonsteroidal AI** and a CDK4/6 inhibitor combi...
....1.7...
...Tamoxifen (, , , )1048203...
...Alternative hormonal treatment (tamox...
...Fulvestrant and a CDK4/6 inhibitor (,...
....1.8
...ic Tamoxifen (, , , )104...
...y reuse specific hormone agent (, , , )1048203...
...nhanced AI** + CDK4/6 inhibitor May reuse...
....1.9...
Basic Tamoxifen (, , , )1048203
...d Tamoxifen or (combined hormone blockage non...
...rmonal therapy (A nonsteroidal AI and a...
...-Positive...
....2.1
...alliative* and best supportive care (, , , )1...
Limited Chemotherapy, options inc...
...ced HER2-targeted therapy combin...
....2.2...
Basic Single-agent hormone therap...
...ngle-agent chemotherapy with anthracyclines,...
...ced HER2-targeted therapy (trastuzumab...
...ple-Negativ...
....3.1...
...c Palliative* and best supportive care...
...e-agent chemotherapy (, , , )1048203...
...d Single-agent chemotherapy rather than combina...
1.3....
...Palliative* and best supportive care (,...
Limited Single-agent chemotherapy Combination...
...ingle-agent chemotherapy Combination...
....3.3...
Basic Palliative* and best supportive...
...ited Single-agent chemotherapy (,...
...Addition of immune checkpoint inhibitor to c...
...Mutations (note: the recommendations for patien...
....4.1....
...en — If ER-positive, then see ER-positive recom...
...ited Tamoxifen with OA AI with...
...RPi Single-agent chemotherapy rathe...
1.4.1....
...ic Palliative* and best supportive care (,...
...le-agent chemotherapy (, , , )1048203...
...iD/Chemotherapy (, , , )1048203...
....4.2
...tive* and best supportive care (, , , )10482...
Limited Single-agent chemotherapy,...
Enhanced PARPi (in the first- thro...
...Line Systemic Metastatic Breast Cancer Treatme...
...n Basic settings, the recommendations pr...
...Positive, HER2-Negative...
....1.1
...ic Palliative* and best supportive care (, , ,...
...-agent chemotherapy, combination regimens may...
...anced Single-agent chemotherapy, combi...
2.1....
Basic Tamoxifen if previously not...
...amoxifen or single-agent chemotherapy, combinatio...
...emestane and everolimus (, , , )1048203...
2.1....
...tive* and best supportive care (, , , )1...
...oxifen or single-agent* chemotherapy, co...
...elisib in combination with endocrine therapy in c...
2.1....
...ve* and best supportive care (, , , )1048203...
...Tamoxifen or single-agent chemotherapy, combin...
...Endocrine therapy, AI, or fulvestrant ± eve...
2.1....
...therapy Palliative* care and best support...
...e-agent chemotherapy, combination regim...
...one therapy with or without targete...
....1.6...
...Palliative* and best supportive care (, ,...
...ngle-agent chemotherapy, combination reg...
...nced PARPi Single-agent chemother...
...-Positive
2.2.1
...ve* and best supportive care (HER2 testing...
...imited Chemotherapy (anthracyclines, docetaxel...
...ed (1) Trastuzumab deruxtecan....
....2.2...
Basic (Total mastectomy for ipsil...
...ted Chemotherapy with anthracyclines,...
...Trastuzumab deruxtecan. If 1 not availab...
2.2.3
...liative* and best supportive care (, , ,...
...Chemotherapy (anthracyclines, docetaxel...
...(1) Trastuzumab deruxtecan. I...
2.2....
...Palliative* and best supportive care (, , , )...
...otherapy (anthracyclines, once weekl...
...d HER2-targeted therapy combined...
...riple-Negative
2.3....
...lliative* and best supportive care (, , , )1...
...Single-agent chemotherapy; start...
...ced Single-agent chemotherapy rather...
...able 5. Maximal Setting: Third-line Options for H...
...ined = not on EML Italics = medica...
...ient’s HER2-positive advanced bre...
...a patient has not received trastuzumab emtan...
...ined with trastuzumab and capecitabine (, , ,...
...deruxtecan (, , , S)1048203...
Neratinib combined with capecitabine (...
...inib and trastuzumab (, , , W)1048...
Lapatinib and capecitabine (, , , W)1048203
...inations of chemotherapy and trastuzum...
...tuximab plus chemotherapy (, , , W)104...
...has not received pertuzumab, pertuzumab (, , , W)1...
...py (in patients with ER-positive and/or Pg...
Abemaciclib combined with trastuzuma...
...ble 6. Third-Line and Beyond Systemic M...
...tings, the recommendations presume that neithe...
...iple-Negative...
3.1.1
...lliative* and best supportive care (, , , )1...
Limited Palliative* and best supportive ca...
...hanced Single-agent chemotherapy rather...
3.1....
...ic Palliative* and best supportiv...
...ARPi (for those with known mutatio...
...PARPi (for those with known mutation status) (,...
...R-positive, BRCA mutation...
....2.1
...sic Palliative* and best supportive ca...
...PARPi (for those with known mutation status) (...
...nced PARPi (for those with known mutation sta...
HER2-Posi...
....3.1...
...iative* and best supportive care (, , , )104...
...ited Chemotherapy (, , , )...
...stuzumab emtansine (, , , )1048203...
3.3....
...ve* and best supportive care (, , , )10...
...ited Hormonal therapy (, , , )10482...
...stuzumab + hormonal therapy (, , , )1048203...
3.3....
...Not relevant (, , , )1048203...
...If a patient is receiving HER2-targ...
...ced If a patient is receiving HER2-ta...
...ASCO believes that cancer clinical trials are v...